Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated at UBS Group

Equities research analysts at UBS Group assumed coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a report issued on Monday, MarketBeat reports. The brokerage set a “neutral” rating on the stock.

JSPR has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Thursday, January 22nd. Rodman & Renshaw initiated coverage on Jasper Therapeutics in a report on Tuesday, January 13th. They set a “buy” rating and a $17.00 target price on the stock. Six equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Jasper Therapeutics presently has a consensus rating of “Hold” and an average target price of $19.88.

Jasper Therapeutics Trading Down 3.4%

Shares of Jasper Therapeutics stock opened at $1.15 on Monday. Jasper Therapeutics has a twelve month low of $1.11 and a twelve month high of $7.19. The stock has a market cap of $32.18 million, a price-to-earnings ratio of -0.19 and a beta of 3.08. The company has a fifty day moving average price of $1.37 and a 200 day moving average price of $1.82.

Institutional Trading of Jasper Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Acadian Asset Management LLC acquired a new stake in Jasper Therapeutics in the first quarter valued at $46,000. Marex Group plc acquired a new position in Jasper Therapeutics during the 2nd quarter worth $74,000. Engineers Gate Manager LP bought a new stake in shares of Jasper Therapeutics in the 2nd quarter worth about $78,000. Panagora Asset Management Inc. acquired a new stake in shares of Jasper Therapeutics in the 4th quarter valued at about $35,000. Finally, Voleon Capital Management LP acquired a new stake in shares of Jasper Therapeutics in the 3rd quarter valued at about $50,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.